The Latest Breaking News from FDA

As the debate over mifepristone makes its way to the Supreme Court, the pharmaceutical industry has raised concerns that ruling against the FDA could chill the development of new drugs.

The conservative 5th Circuit has blocked part of a Texas judge’s decision to pull abortion drug mifepristone off the market, but leaves in place onerous and outdated restrictions that the Food and Drug Administration determined in 2016 were medically unnecessary.

Interest has exploded in a weight loss drug that was initially developed to help diabetics control their blood sugar.

PITTSBURGH — A paper published Tuesday in the journal Respiratory Research adds to a growing body of research that shows menthol flavoring added to electronic cigarette liquid worsens lung damage. The study represents the first time, to the authors' knowledge, that these effects have been seen with aerosolized menthol vapor.

FDA commissioner Robert Califf said in an interview that aired this week that misinformation is killing Americans — contributing to the fact that our life expectancy is 3 to 5 years worse than that of people in comparably wealthy countries. He called for better regulation to crack down on misinformation.…

The appeals court's unpublished order avoids some of the district court's errors, but still has some significant problems, especially with regard to standing.

WASHINGTON — Attorney General Merrick Garland said Thursday that the Biden administration will ask the Supreme Court to preserve full and easy access to the abortion medication that has become the most-used method of ending early pregnancies.

Missouri minors will soon be required to go through 18 months of therapy before receiving any gender-affirming health care

Doctors, clinics and telehealth providers across the country are scrambling to figure out how they will continue to provide the most common type of abortion after a federal appeals court imposed new restrictions on a key abortion medication

The decision comes shortly after an appeals court left numerous restrictions on abortion pill access in place.

It’s not the FDA’s job to tell doctors what to do.